Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature

Table 1

Patient natural history.

Date	Treatments	Comments
April 1999	Surgery (total resection)-	DFI/6 years
	Craniospinal irradiation (35 Gy) + boost PCF (18 Gy) total dose 54 Gy
March 2005	Relapse (cervico-dorsal spinal cord)	Progression after 8 months
	Chemotherapy (dacarbazine-vp16- CDDP/carboplatin 6 cycles)
November 2005	Relapse (brain stem and cervical spinal cord)	Partial response PFI 13 months
	Chemotherapy (procarbazine-lomustine 2 cycles)
	Reirradiation (brainstem and spinal cord 24 Gy) plus concomitant temozolomide
	Temozolomide (13 cycles until December 2006)
January 2007	Relapse (sacral spinal)	Progressive disease
	Chemotherapy (vincristine-VP16-ifosfamide-2 cycles)
April 2007	Relapse (brain)	Complete response
	Targeted therapy (bevacizumab q.14 3 months)
October 2007	Arterious hypertension	Progressive disease
	Targeted therapy (bevacizumab q.21 4 months)
February 2008	Relapse (cervical spinal cord)	Partial response
	Targeted therapy (bevacizumab q.14 7 months until September 2008)
October 2008	Cerebral hygroma/epileptic syndrome	Death